articleThe LancetApr 1, 2020GREEN OA

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

Willamette Valley Cancer Institute and Research Center · Somogy Megyei Kaposi Mór Oktató Kórház · +29 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

No related works found for this paper.